Phosphatidylinositol 3-Kinase Is a Determinant of Responsiveness to B Cell Antigen Receptor-Mediated Epstein-Barr Virus Activation

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1561-1566

  Iwakiri, Dai ^a   Takada, Kenzo ^a,b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Institute for Genetic Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SOMATOMEDIN C; UNCLASSIFIED DRUG; VIRUS PROTEIN; WORTMANNIN;

AKATA CELL LINE; ARTICLE; BURKITT LYMPHOMA; CELL LINE; CONTROLLED STUDY; CROSS REACTION; DAUDI CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR BIOLOGY; MUTU I CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; VIRUS ACTIVATION;

EID: 1642444166     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1561     Document Type: Article

References (34)

1. Rickinson, A. B., and E. Kieff. 2002. Epstein-Barr virus. In Fields Virology. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven. Philadelphia, p. 2575.
2. Gerber, P. 1972. Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes). Proc. Natl. Acad. Sci. USA 69:83.
3. Hampar, B., J. G. Derge, L. M. Martos, and J. L. Walker. 1972. Synthesis of Epstein-Barr virus after activation of the viral genome in a "virus-negative" human lymphoblastoid cell (Raji) made resistant to 5-bromodeoxyuridine (thymidine kinase-virus antigen-immunofluorescence-herpesvirus fingerprints). Proc. Natl. Acad. Sci. USA 69:78.
4. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecher. 1978. Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature 272:373.
5. Tovey, M., G. Lenoir, and J. Lours-Begon. 1978. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276:270.
6. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 33:27.
7. Luka, J., B. Kallin, and G. Klein. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228.
8. Weiss, A., and D. R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. Cell 76:263.
9. DeFranco, A. L. 1997. The complexity of signaling pathways activated by the BCR. Curr. Opin. Immunol. 9:296.
10. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445.
11. Takada, K., K. Horinouchi, Y. Ono, T. Aya, T. Osato, M. Takahashi, and S. Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5:147.
12. Shimizu, N., H. Yoshiyama, and K. Takada. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70:7260.
13. Keiff, E., and A. B. Rickinson. 2002. Epstein-Barr virus and its replication. In Fields Virology. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, p. 2511.
14. Miller, C. L., J. H. Lee, E. Kieff, and R. Longnecker. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin cross-linking. Proc. Natl. Acad. Sci. USA 91:772.
15. Miller, C. L., A. L. Burkhardt, J. H. Lee, B. Stealey, R. Longnecker, J. B. Bolen, and E. Kieff. 1995. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155.
16. Konishi, K., S. Maruo, H. Kato, and K. Takada. 2001. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J. Gen. Virol. 82:1451.
17. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481.
18. Klein, E., G. Klein, J. S. Nadkarni, J. J. Nadkarni, H. Wigzell, and P. Clifford. 1968. Surface IgM-κ specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28:1300.
19. Nanbo, A., K. Inoue, K. Adachi-Takasawa, and K. Takada. 2002. Epstein-Barr virus RNA confers resistance to interferon-a-induced apoptosis in Burkitt's lymphoma. EMBO J. 21:954.
20. Furstenberger, G., and H. J. Senn. 2002. Insulin-like growth factors and cancer, Lancet Oncol. 3:298.
21. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. Trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016.
22. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:085.
23. Zimber, S. U., E. Kremmer, F. Grasser, G. Marchall, G. Laux, and G. W. Bornkamm. 1993. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J. 12:167.
24. Chen, F., J. Zou, L. di Renzo, G. Winberg, L. Hu, E. Klein, G. Klein, and 1. Ernberg. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69:3752.
25. Miyashita, E. M., B. Yang, G. J. Babcock, and D. A. Thorley-Lawson. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71:4882.
26. Qu, L., and D. Rowe. 1992. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66:3715.
27. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374.
28. Niiro, H., A. Maeda, T. Kurosaki, and E. A. Clark. 2002. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J. Exp. Med. 195:143.
29. 2+. Eur. J. Immunol. 6:1576.
30. Daibata, M., R. E. Humphreys, K. Takada, and T. Sairenji. 1990. Activation of latent Epstein-Barr virus via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J. Immunol. 144:4788.
31. Satoh, T., Y. Hoshikawa, Y. Satoh, T. Kurata, and T. Sairenji. 1999. The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells. Virus Genes 18:57.
32. Adamson, A. L., D. Darr, E. Holley-Guthrie, R. A. Johnson, A. Mauser, J. Swenson, and S. Kenney. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74:1224.
33. Darr, C. D., A. Mauser, and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 5:6135.
34. Wakabayashi, C., T. Adachi, J. Wienands, and T. Tsubata. 2002. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298:2392.